Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Issue 18 (25th April 2018)

• Record Type: Journal Article
• Authors: Yang, Huiqiang; Yang, Huan; Li, Zhushi; Liu, Lina; Wang, Wei; He, Ting; Fan, Fengming; Sun, Yan; Liu, Jie; Li, Yuhua; Zeng, Xianwu
• Is Part Of: Vaccine. Volume 36:Issue 18(2018)
• Page Start: 2450
• Page End: 2455
• Publication Date: 2018-04-25
• Subjects: Yellow fever vaccine -- Serious adverse events -- Chimeri-JYF -- Japanese encephalitis virus -- Safe -- Protection; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2018.03.038
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Yellow fever (YF) is an acute viral haemorrhagic disease caused by the yellow fever virus (YFV), which remains a potential threat to public health. The live-attenuated YF vaccine (17D strain) is a safe and highly effective measure against YF. However, increasing adverse events have been associated with YF vaccinations in recent years; thus, safer, alternative vaccines are needed. In this study, using the Japanese encephalitis live vaccine strain SA14-14–2 as a backbone, a novel chimeric virus was constructed by replacing the pre-membrane (prM) and envelope (E) genes with their YFV 17D counterparts.The chimeric virus exhibited a reduced growth rate and a much smaller plaque morphology than did either parental virus. Furthermore, the chimera was much less neurovirulent than was YF17D and protected mice that were challenged with a lethal dose of the YF virus. These results suggest that this chimera has potential as a novel attenuated YF vaccine.